Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2107)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (105)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (846)
  3. JNCI: Journal of the National Cancer Institute (485)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4652)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical characteristics, efficacy, and safety in patients receiving second- or third-line encorafenib plus cetuximab (E+C) vs control for metastatic colorectal cancer (mCRC): BEACON CRC post hoc analysis
    Meeting Abstract

    Tabernero, J.; Van Cutsem, E.; Yoshino, T.; Yaeger, R.; Wasan, H.; Desai, J.; Ciardiello, F.; Alkuzweny, B.; Zhang, X.; Guenzil, C.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Outcomes in advanced hepatocellular carcinoma (HCC) patients (pts) treated with immune checkpoint inhibitors (ICI)
    Meeting Abstract

    Cowzer, D.; Capanu, M.; Keane, F.; Khalil, D.; Shia, J.; Do, R.; Chou, J.; Walch, H.; El Dika, I.; Yaqubie, A.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH1 and IDH2, as monotherapy and in combination with cisplatin and gemcitabine in advanced IDH-mutant cholangiocarcinoma
    Meeting Abstract

    Harding, J.; Ikeda, M.; Goyal, L.; Rodon, J.; Bai, L.; Oh, D.; Park, J.; Chen, L.; Ueno, M.; Liao, C.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Quantitative risk-benefit assessment of ivosidenib compared to placebo in patients with IDH1-mutated intrahepatic cholangiocarcinoma: Phase 3 ClarIDHy trial
    Meeting Abstract

    Valle, J.; Abou-Alfa, G.; Kelley, R.; Lowery, M.; Shroff, R.; Bian, Y.; Saint-Hilary, G.; Liu, H.; Teng, Z.; Hua, Z.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Patients (pts) with advanced hepatocellular carcinoma (HCC) with long-term response to immune checkpoint inhibitor (ICI) therapy
    Meeting Abstract

    Keane, F.; Cowzer, D.; Khalil, D.; Shia, J.; Do, R.; Folorunso, S.; El Dika, I.; Yaqubie, A.; Kim, T.; O'Reilly, E.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion gastrointestinal (GI) cancer: An updated analysis
    Meeting Abstract

    AndreĢ, T.; Hong, D.; Deeken, J.; Italiano, A.; Liu, T.; Burcoveanu, D.; Norenberg, R.; Mussi, C.; Xu, R.; Drilon, A.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • TROPION-PanTumor03, a phase 2, multicentre study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients with advanced/metastatic solid tumours: Substudies in gastric and colorectal cancer
    Meeting Abstract

    Oaknin, A.; Meric-Bernstam, F.; Lang, J.; Ciombor, K.; Ray-Coquard, I.; Oza, A.; Yonemori, K.; Xu, R.; Zhao, J.; Gajavelli, S.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations
    Meeting Abstract

    Harding, J.; Perez, C.; Kato, S.; Sharma, M.; Garmezy, B.; Quah, C.; Tam, B.; Severson, P.
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Brightline-2: A phase IIa/IIb, open-label trial of the MDM2-p53 antagonist BI 907828 in patients with advanced MDM2-amplified, TP53 wild-type biliary tract cancer, pancreatic ductal adenocarcinoma, or other selected solid tumours
    Meeting Abstract

    Macarulla, T.; Harding, J.; Morizane, C.; Ohkawa, K.; Ueno, M.; Vogel, A.; Lamarca, A.; Yamamoto, N.; Javle, M.; Hu, J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • NALIRIFOX (iposomal irinotecan + 5-fluorouracil/feucovorin + oxaliplatin) versus FOLFOX [5-fluorouracil/leucovorin + oxaliplatin] as first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): Real-world comparative overall survival
    Meeting Abstract

    O'Reilly, E.; Li, J.; DerSarkissian, M.; Chang, R.; Cheng, M.; Yu, L.; Rane, D.; Zhang, L.; Xiao, Z.; Benzaghou, F.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save